Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

This study has been terminated.
(After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome.)
Information provided by (Responsible Party):
Novartis Identifier:
First received: March 4, 2008
Last updated: April 25, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 25, 2016